# A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)

Study · id `cardio:ct-nct01156571` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01156571](<https://clinicaltrials.gov/study/NCT01156571>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01156571

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 11145 participants.

## Technical summary

Registry record NCT01156571. Randomized; quadruple masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-12 (actual). Results posted on 2013-06-18.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 11145 participants (enrolled count; ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Start date: 2010-09 (registry gives no type) (ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Primary completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Completion: 2012-12 (actual) (ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Results first posted: 2013-06-18 (ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01156571, source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01156571-2014-02-04`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)
- Acronym: CHAMPION
- Condition: Atherosclerosis
- Condition: Percutaneous Coronary Intervention
- Condition: Acute Coronary Syndrome
- Intervention (Drug): cangrelor P2Y12 (platelet) inhibitor
- Intervention (Drug): Clopidogrel - 300 or 600 mg (study arm)
- Intervention (Drug): Clopidogrel 600 mg post cangrelor
- Lead sponsor: The Medicines Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: The Medicines Company (`cardio:org-the-medicines-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of platelet inhibition with cangrelor during PCI on ischemic events (`cardio:pubmed-23473369`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention) (`cardio:pubmed-24184169`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial (`cardio:pubmed-26762525`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX (`cardio:pubmed-26400827`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial (`cardio:pubmed-27313282`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition) (`cardio:pubmed-27482008`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial (`cardio:pubmed-27659566`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial (`cardio:pubmed-30203006`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial (`cardio:pubmed-30563770`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX (`cardio:pubmed-34915723`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b557b285187692a2acb390efc06c29941c339afefe2f7435d4b36dab04b05976
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
